Phase Ia/b Study of Giredestrant ±Palbociclib and ±Luteinizing Hormone-releasing Hormone Agonists in Estrogen Receptor-positive, HER2-negative, Locally Advanced/Metastatic Breast Cancer.
Komal L JhaveriMeritxell Bellet-EzquerraNicholas C TurnerSherene LoiAditya BardiaValentina BoniJoo Hyuk SohnTomas G NeilanRafael Villanueva-VázquezPeter KabosLaura García EstévezElena Lopez-MirandaJosé Alejandro Pérez-FidalgoJose Manuel Perez-GarciaJiajie YuJill FredricksonHeather M MooreChing-Wei ChangJohn W BondJennifer Eng-WongMary R GatesElgene LimPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Giredestrant was well tolerated and clinically active in patients who progressed on prior ET. Results warrant further evaluation of giredestrant in randomized trials in early- and late-stage ER+ breast cancer.